Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets

@article{AstonMourney2011Exendin4II,
  title={Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets},
  author={Kathryn Aston-Mourney and Rebecca L Hull and Sakeneh Zraika and Jayalakshmi Udayasankar and Shoba L Subramanian and Steven E Kahn},
  journal={Diabetologia},
  year={2011},
  volume={54},
  pages={1756-1765}
}
In type 2 diabetes, aggregation of islet amyloid polypeptide (IAPP) into amyloid is associated with beta cell loss. As IAPP is co-secreted with insulin, we hypothesised that IAPP secretion is necessary for amyloid formation and that treatments that increase insulin (and IAPP) secretion would thereby increase amyloid formation and toxicity. We also hypothesised that the unique properties of the glucagon-like peptide-1 (GLP-1) receptor agonist exendin-4 to maintain or increase beta cell mass… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

a double-blind placebo-controlled study

  • MA Nauck, RE Ratner, +4 authors alone lowers body weight in patients with type 2 diabete metformin
  • Diabetes Care 32:1237–1243 1764 Diabetologia
  • 2011

a randomized, controlled trial

  • MC Bunck, M Diamant, Corner A et al One-year treatment with exenatide improves function, compared with insulin glargine, in metformin-treated type 2 diabetic patients
  • Diabetes Care 32:762–768 Diabetologia
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…